Clinical Trial Update: An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients [Phase 3]

View source ↗

Summary

Phase III open-label trial comparing Algeron (cepeginterferon alfa-2b) with PegIntron (peginterferon alfa-2b) plus ribavirin in HIV-coinfected chronic hepatitis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Hepatitis in Human Immunodeficiency Virus Coinfection

Drugs mentioned

• Algeron (cepeginterferon alfa-2b)
• PegIntron (pegylated interferon alfa-2b)

Snippet

Sponsor: Biocad | Conditions: Hepatitis, Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-07-21